Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolus (EOLS) Research & Development (2018 - 2025)

Evolus (EOLS) has disclosed Research & Development for 8 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 43.25% year-over-year to $3.5 million, compared with a TTM value of $9.6 million through Dec 2025, up 4.4%, and an annual FY2025 reading of $9.6 million, up 4.4% over the prior year.
  • Research & Development was $3.5 million for Q4 2025 at Evolus, up from $2.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.5 million in Q4 2025 and bottomed at $301000.0 in Q3 2021.
  • Average Research & Development over 5 years is $1.6 million, with a median of $1.6 million recorded in 2022.
  • Peak annual rise in Research & Development hit 357.14% in 2022, while the deepest fall reached 44.35% in 2022.
  • Year by year, Research & Development stood at $423000.0 in 2021, then surged by 218.68% to $1.3 million in 2022, then skyrocketed by 76.56% to $2.4 million in 2023, then grew by 2.1% to $2.4 million in 2024, then surged by 43.25% to $3.5 million in 2025.
  • Business Quant data shows Research & Development for EOLS at $3.5 million in Q4 2025, $2.0 million in Q3 2025, and $1.8 million in Q2 2025.